HK1250176A1 - 用於确定细胞疗法的临床反应的生物标志物 - Google Patents

用於确定细胞疗法的临床反应的生物标志物 Download PDF

Info

Publication number
HK1250176A1
HK1250176A1 HK18109614.7A HK18109614A HK1250176A1 HK 1250176 A1 HK1250176 A1 HK 1250176A1 HK 18109614 A HK18109614 A HK 18109614A HK 1250176 A1 HK1250176 A1 HK 1250176A1
Authority
HK
Hong Kong
Prior art keywords
clinical response
biomarkers
determining
cell therapy
mscs
Prior art date
Application number
HK18109614.7A
Other languages
English (en)
Chinese (zh)
Inventor
Olga De La Rosa
Wilfried Dalemans
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HK1250176A1 publication Critical patent/HK1250176A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7156—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ecology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
HK18109614.7A 2015-04-24 2016-04-25 用於确定细胞疗法的临床反应的生物标志物 HK1250176A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382206 2015-04-24
EP15382206.9 2015-04-24
PCT/EP2016/059196 WO2016170187A2 (en) 2015-04-24 2016-04-25 Biomarkers for determining the clinical response to cell therapy

Publications (1)

Publication Number Publication Date
HK1250176A1 true HK1250176A1 (zh) 2018-11-30

Family

ID=53015749

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109614.7A HK1250176A1 (zh) 2015-04-24 2016-04-25 用於确定细胞疗法的临床反应的生物标志物

Country Status (7)

Country Link
US (1) US10746729B2 (enExample)
EP (1) EP3286562B1 (enExample)
JP (1) JP6811724B2 (enExample)
CA (1) CA2983950A1 (enExample)
HK (1) HK1250176A1 (enExample)
IL (1) IL255243B (enExample)
WO (1) WO2016170187A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12303534B2 (en) 2018-06-05 2025-05-20 Medipost Co., Ltd Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
WO2020009648A1 (en) * 2018-07-02 2020-01-09 Nextcell Pharma Ab Msc prediction algorithm
JP7628499B2 (ja) * 2019-02-27 2025-02-10 武田薬品工業株式会社 同種異系療法のための改良された幹細胞集団

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
ES2595103T3 (es) * 2007-10-17 2016-12-27 Txcell Células Tr1, células madre mesenquimales y usos de estas
US20140219921A1 (en) * 2012-12-21 2014-08-07 Rutgers, The State University Of New Jersey Immunomodulating compositions and methods
ES2748825T3 (es) * 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular
US20160120910A1 (en) * 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
JP6811724B2 (ja) 2021-01-13
EP3286562B1 (en) 2020-08-12
US10746729B2 (en) 2020-08-18
WO2016170187A3 (en) 2016-12-01
EP3286562A2 (en) 2018-02-28
IL255243B (en) 2021-04-29
IL255243A0 (en) 2017-12-31
US20180156785A1 (en) 2018-06-07
WO2016170187A2 (en) 2016-10-27
CA2983950A1 (en) 2016-10-27
JP2018513388A (ja) 2018-05-24

Similar Documents

Publication Publication Date Title
WO2014004990A3 (en) Methods for determining drug efficacy using cereblon-associated proteins
BR112013004750A2 (pt) derivados de quinolina e quinoxalina como inibidores da cinase
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
HK1209835A1 (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
HK1250752A1 (zh) 治疗骨髓增生性障碍的方法
TN2013000412A1 (en) Bcma-based stratification and therapy for multiple myeloma patients
EA202091568A1 (ru) Ингибиторы глюкозилцерамид-синтазы
DK3083997T3 (da) Diagnostiske, prognostiske og terapeutiske anvendelser af lange ikke-kodende rna¿er til hjertelidelser og regenerativ lægemiddel
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
MX2012010418A (es) Inhibidores syk de imidazopiridinas.
GB201309758D0 (en) Generation of neural stem cells from human trophoblast stem cells
MX2016011612A (es) Determinacion de agresividad, pronostico y responsividad del cancer al tratamiento.
EA201690746A1 (ru) Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
AR088514A1 (es) Inmunoligantes biespecificos dirigidos contra tnf
WO2013124815A3 (en) Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
EA201691094A1 (ru) Получение антител для конъюгации из культур клеток cho
EP4286847A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2015069883A8 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
WO2016170187A3 (en) Biomarkers for determining the clinical response to cell therapy
WO2015120436A3 (en) Stat3 phosphorylation during graft-versus-host disease
MX2015009726A (es) Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos.
EP4289970A3 (en) Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis